Newsfeeds Archive - Spark Newswire

1 minute read

Merrimack Pharmaceuticals Announces Approval Of Plan Of Dissolution And Cash Liquidating Dividend Amount Of $15.10 Per Share

May 10, 4:36 PM

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that

MACK

6 minute read

Ipsen’s Onivyde Regimen, A Potential New Standard-Of-Care First-Line Therapy In Metastatic Pancreatic Adenocarcinoma, Approved By FDA

By Benzinga Newsdesk

February 13, 5:50 PM

Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde® regimen (NALIRIFOX) demonstrated statistically significant superiority and clinically meaningful improvements in overall survival and

IPSEY

2 minute read

FDA Approves Irinotecan Liposome For First-line Treatment Of Metastatic Pancreatic Adenocarcinoma

By Benzinga Newsdesk

February 13, 2:19 PM

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-irinotecan-liposome-first-line-treatment-metastatic-pancreatic-adenocarcinomaOn February 13, 2024, the Food and Drug Administration approved

IPSEY

2 minute read

$2M Bet On Ford? Check Out These 4 Stocks Insiders Are Buying

By Avi Kapoor

December 12, 7:46 AM

Although U.S. stocks closed higher on Monday, there were a few notable insider trades.

2 minute read

Luna Innovations, Guess? And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

By Lisa Levin

March 15, 7:21 AM

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

BORR

1 minute read

Merrimack Pharmaceuticals FY22 EPS (0.11) Vs $(0.18) YoY

By Happy Mohamed

March 9, 5:43 PM

Full Year 2022 Financial Results Merrimack reported net loss of $1.5 million for the year ended December 31, 2022, or $0.11 per basic share, compared to a net loss of $2.5 million,

MACK